A Bernareggi
Overview
Explore the profile of A Bernareggi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bernareggi A, Luin E, Pavan B, Parato G, Sciancalepore M, Urbani R, et al.
Acta Physiol (Oxf)
. 2015 Feb;
214(4):467-80.
PMID: 25683861
Aims: The autocrine activity of the embryonic isoform of the nicotinic acetylcholine receptor is crucial for the correct differentiation and trophism of skeletal muscle cells before innervation. The functional activity...
2.
Lim S, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, et al.
Leuk Lymphoma
. 2007 Feb;
48(2):374-80.
PMID: 17325899
The purpose of the study was to evaluate the safety, efficacy, and pharmacokinetics of pixantrone (BBR2778) when substituted for etoposide in the ESHAP regimen in patients with aggressive relapsed or...
3.
Borchmann P, Schnell R, Knippertz R, Staak J, Camboni G, Bernareggi A, et al.
Ann Oncol
. 2001 Jul;
12(5):661-7.
PMID: 11432625
Background: BBR 2778 is a novel aza-anthracenedione showing no cardiotoxicity and superior activity compared to doxorubicin and mitoxantrone in animal models. Objectives of this phase I study included the determination...
4.
Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, et al.
Clin Cancer Res
. 2001 Feb;
7(1):43-50.
PMID: 11205916
BBR 2778 is a novel aza-anthracenedione with no cardiotoxicity in preclinical models. This Phase I dose escalation trial of BBR 2778 was conducted to determine the maximum tolerated dose, the...
5.
Dawson L, Jodrell D, Bowman A, Rye R, Byrne B, Bernareggi A, et al.
Eur J Cancer
. 2000 Nov;
36(18):2353-9.
PMID: 11094309
The anthracenedione analogue, BBR 2778 is an active antitumour agent preclinically and has reduced potential for cardiotoxicity compared with other similar drugs in preclinical models. BBR 2778 was administered 3...
6.
Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, et al.
Ann Oncol
. 2000 Oct;
11(8):977-83.
PMID: 11038034
Objectives: To define the maximum tolerated dose (MTD), the toxicity and pharmacokinetic profile of BBR3464, a novel triplatinum complex. Patients And Methods: Fourteen patients with advanced solid tumors not responsive...
7.
Bernareggi A
Clin Pharmacokinet
. 1998 Nov;
35(4):247-74.
PMID: 9812177
Nimesulide is a selective COX-2 inhibitor used in a variety of inflammatory, pain and fever states. After healthy volunteers received oral nimesulide 100 mg in tablet, granule or suspension form...
8.
Di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta E, Formento M
Anticancer Res
. 1998 Aug;
18(4C):3113-7.
PMID: 9713519
BBR 3464 is a novel trinuclear platinum anticancer agent designed on the hypothesis that new clinically useful platinum based anticancer agents should have novel structures unrelated to those of agents...
9.
Bernareggi A, Crippa M, Bastrup U, Di Giovine S, Cesarini R, Tognella S
Boll Chim Farm
. 1997 Apr;
136(4):304-7.
PMID: 9281891
No abstract available.
10.
Torti L, Bernareggi A, Castoldi D, Formento M, Cesarini R, Tognella S
Boll Chim Farm
. 1997 Apr;
136(4):301-3.
PMID: 9281890
No abstract available.